This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relap…

Breast CancerRelapseResistant Cancer+1 more

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06347068

Phase 1

A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen…

Pancreas CancerRelapseResistant Cancer

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06158139